Comparison of pH-adjusted bupivacaine 0.75% and a mixture of bupivacaine 0.75% and lidocaine 2%, both with hyaluronidase, in day-case cataract surgery under regional anesthesia.
Alkalinized bupivacaine 0.75% (pH 6.8) and a mixture (1:1) of bupivacaine 0.75% and lidocaine 2%, both with hyaluronidase, were compared in regional ophthalmic anesthesia for day-case cataract surgery. Eighty-two patients were randomized into two groups (n = 39 and 43) to receive one of the two solutions in a double-blind manner. Two intraorbital injections were administered initially: an inferolateral intraconal injection (3 mL) and a medial extraconal injection (3.5 mL). The progress of lid and globe akinesia was examined every 2.5 min up to 25 min and postoperatively. The block was supplemented at 10 and 20 min, if needed. Significantly better globe akinesia was achieved with the bupivacaine-lidocaine mixture; the patients who had received alkalinized bupivacaine needed additional injections significantly more often at 10 and 20 min. In lid akinesia, the onset time and recovery were similar in the two groups. One patient in the alkalinized bupivacaine group felt intraoperative pain, and eight patients in the bupivacaine-lidocaine group and seven in the alkalinized bupivacaine group sensed pain postoperatively from corticosteroid and antibiotic injections. Seventy percent of the pH-adjusted bupivacaine group and 8% of the lidocaine-bupivacaine group had diplopia the day after surgery. Of the two local anesthetic mixtures studied, lidocaine (2%) with bupivacaine (0.75%) provided regional ophthalmic anesthesia of better quality.
Sarvela
P J
PJ
Anesthesiology Clinic, Eye Hospital, Helsinki University Central Hospital, Finland.
Paloheimo
M P
MP
Nikki
P H
PH
D000368:Aged; D000556:Ambulatory Surgical Procedures; D000772:Anesthesia, Local / Q000009:adverse effects; D002045:Bupivacaine / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D002387:Cataract Extraction; D004172:Diplopia / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage; D006863:Hydrogen-Ion Concentration; D007267:Injections; D008012:Lidocaine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D010146:Pain / Q000209:etiology; D011183:Postoperative Complications / Q000209:etiology
D008012:Lidocaine; D006821:Hyaluronoglucosaminidase; D002045:Bupivacaine